Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.61 |
| ▸ | TAF1 | P21675 | 4/20 | 0.61 |
| ▸ | CECR2 | Q9BXF3 | 4/20 | 0.61 |
| ▸ | BRD4 | O60885 | 11/20 | 0.50 |
| ▸ | POLR1A | O95602 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753965 | 0.84 | BRD9 (0.72) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17753734 | 0.82 | BRD9 (0.60) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17753966 | 0.81 | BRD9 (0.64) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17753988 | 0.81 | TAF1 (0.58) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17753900 | 0.81 | BRD9 (0.60) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL17754066 | 0.80 | BRD9 (0.62) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL17754077 | 0.80 | BRD9 (0.56) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL19652263 | 0.80 | TAF1 (0.71) | BRD9TAF1CECR2BRD4ATAD2 | |
| SCHEMBL17749030 | 0.80 | TAF1 (0.61) | BRD9TAF1CECR2BRD4 | |
| SCHEMBL17753963 | 0.80 | BRD9 (0.61) | BRD9TAF1CECR2BRD4ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | BRD9 16/4885TAF1 439/4885CECR2 184/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | BRD9 16/4885TAF1 439/4885CECR2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.